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Cabazitaxel in the treatment of metastatic 
castration-resistant prostate cancer: patient 
selection and special considerations
Sheel A Patel
Jean Hoffman-Censits
Department of Medical Oncology, 
Sidney Kimmel Cancer Center, 
Thomas Jefferson University, 
Philadelphia, PA, USA
Abstract: Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic 
castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new 
antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are 
now multiple effective and approved agents for this disease state. The optimal sequencing of 
these agents is unclear as there are no large-scale head-to-head comparisons. Clinicians must 
familiarize themselves with the most recent studies as well as drug toxicities to determine the 
best treatment option for their patients. In this review, we focus on the development of cabazi-
taxel for mCRPC, evaluate its efficacy, and highlight key strategies for toxicity management. 
Additionally, we summarize the studies that address cabazitaxel treatment sequencing and 
optimal dosing schedule.
Keywords: sequencing, clinical trials, docetaxel, abiraterone, enzalutamide, biomarkers
Introduction
Prostate cancer is the second most common tumor in men in the United States. 
The annual mortality rate has slowly declined over the past years possibly related to 
improved screening and curative treatment for early stage disease. Unfortunately, men 
with metastatic disease have a 5-year survival rate of only 28% compared to ~100% 
for local and regional stage diseases.1 This large discrepancy is due to the develop-
ment of castrate-resistant metastatic disease, a more aggressive lethal phenotype with 
a distinct biology from castrate-sensitive tumors.
Until this past decade, there were few treatment options available to clinicians 
treating metastatic castration-resistant prostate cancer (mCRPC). The leading treat-
ments were estramustine and mitoxantrone, both of which had little objective data for 
response. In 2004, the US Food and Drug Administration (FDA)-approved docetaxel 
as the first chemotherapeutic agent with overall survival (OS) benefit in mCRPC.2 
In the past 6 years, the treatment arsenal of agents that improve OS in mCRPC has 
rapidly expanded to include sipuleucel-T, abiraterone, enzalutaminde, radium-223, 
and cabazitaxel. Currently, these agents are given sequentially, at the discretion of the 
treating physician, with little objective information other than the medical comorbidi-
ties and choice of the patient, in driving treatment sequence decisions. Although in 
the future, biomarker data may more globally inform sequencing of prostate cancer 
therapy, currently physician and patient preference drive most treatment decisions.
In this review, we focus on the clinical development of cabazitaxel and analyze 
data demonstrating its benefit on OS in men with mCRPC and data that may help 
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practitioners with sequencing, dose modifications, and patient 
selection for cabazitaxel therapy.
Mechanism of action
Taxane chemotherapy significantly changed the treatment 
landscape in mCRPC. In addition to inducing apoptosis by 
microtubule disruption, taxanes have been shown to decrease 
translocation of the androgen receptor (AR) to the nucleus in 
prostate cancer cells as well as decrease transcription of the AR 
protein.3 Docetaxel proved to be a potent semisynthetic taxane 
analog in mCRPC, improving OS when compared to the his-
toric standard mitoxantrone, and it remained the only standard 
in mCRPC for over a decade.2 Unfortunately, use of the drug 
was limited for many patients due to treatment intolerance from 
neuropathy, serositis, or refractory cytopenias. Additionally, 
acquired tumor resistance to docetaxel and cases of primary resis-
tance were recognized as limitations for its continued use.
Cabazitaxel was developed due to its ability to overcome 
tumor resistance to taxanes. Preclinical models of multidrug-
resistant human and murine cancer cell lines demonstrated 
improved cytotoxicity with cabazitaxel compared to docetaxel. 
Unlike its parent drugs, cabazitaxel has poor binding to the ade-
nosine triphosphate-dependent drug efflux pump P glycoprotein 
(P-gp) 1.4 This allows the drug to accumulate intracellularly at 
greater concentrations than docetaxel and is thought to be part 
of the mechanism for improved cabazitaxel cytoxicity.5
Cabazitaxel clinical development
Cabazitaxel (formerly XRP6258) was initially tested in a 
Phase I trial in 25 patients with metastatic solid malignan-
cies, eight of whom had mCRPC. Participants had two 
or fewer previous lines of therapy and 32% had previous 
taxane exposure.4 Doses were escalated from 10 mg/m2 to 
the maximum tolerated dose of 25 mg/m2 and limited due 
to neutropenia events. Interestingly, four patients achieved 
a partial response, two of whom had mCRPC.
Cabazitaxel in the second line and 
beyond
These data supported the initiation of the international Phase 
III TROPIC trial, which opened in 2007.6 Seven hundred 
fifty-five men with mCRPC who had disease progression 
by Response Evaluation Criteria in Solid Tumor (RECIST) 
or prostate specific antigen (PSA) criteria during or after 
docetaxel were randomized to treatment with mitoxantrone 
(12 mg/m2) and prednisone 10 mg daily vs cabazitaxel 
(25 mg/m2) and prednisone. Therapy was given once every 
3 weeks, and the primary end point was OS.
The patient characteristics between both arms were 
comparable, with 50% of the study population having mea-
surable soft tissue disease and 25% with visceral disease. Fol-
lowing enrollment of the first 59 patients, inclusion criteria 
were amended to exclude patients treated with ,225 mg/m2 
cumulative dose of docetaxel, in accordance with updated 
docetaxel guidelines recommending at least 12 weeks of 
therapy prior to making treatment change decisions. With a 
median follow-up of 12.8 months, the primary end point of 
OS in the intent to treat population was 15.1 months in the 
cabazitaxel group compared to 12.7 months in the mitox-
antrone group, demonstrating a 30% relative risk reduction 
of death (P,0.0001). Progression-free survival (PFS) was 
also statistically better in the cabazitaxel group compared 
with the mitoxantrone group (2.8 vs 1.4 months, P,0.0001). 
A subgroup analysis showed that patients with measurable 
disease had significantly better tumor response rate (14.1% 
vs 4.4%, P=0.0005) and PSA response rate with cabazitaxel 
compared with mitoxantrone (39.2% vs 17.8%, P=0.0002). 
As demonstrated in the Phase I trial, there was a high rate of 
febrile neutropenia compared to mitoxantrone (8% vs 1%). 
Nonhematological adverse events with cabazitaxel were 
similar to that in the Phase I study with 47% diarrhea and 
37% fatigue. The rate of neuropathy in this cohort was only 
14%. In general, dose reductions were more common in the 
cabazitaxel group; however, more cycles of cabazitaxel were 
delivered compared to mitoxantrone (6 vs 4).
Though OS was improved with cabazitaxel, there were 
18 treatment-related deaths compared to 9 deaths with 
mitoxantrone. The most common cause of death was neu-
tropenic sepsis (7/18 deaths). Supportive growth factor was 
not permitted with cycle 1 of therapy, but management of 
neutropenia thereafter was at the discretion of the treating 
physician per guidelines. There were five cardiac-related 
deaths on the cabazitaxel arm, with none reported in the 
mitoxantrone-treated subjects. Given the overall benefit, 
the FDA-approved cabazitaxel for men with mCRPC with 
disease progression following docetaxel in 2010.
Subsequent use of cabazitaxel, such as in the German 
Compassionate use Programme, employed closer complete 
blood count monitoring, with 17.1% of patients treated with 
granulocyte colony stimulating factor (G-CSF).7 There was 
1.8% incidence of neutropenic fever among 111 patients, with 
four infection- or hematological-related deaths reported. In the 
United Kingdom Early Access Programme (UK EAP), 112 
docetaxel refractory patients were treated with cabazitaxel 
25 mg/m2.8 Primary G-CSF prophylaxis was recommended 
as per American Society of Clinical Oncology guidelines 
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and was administered in 79.5% of patients initially and, 
subsequently, a total of 84.8% of patients received G-CSF. 
The neutropenic sepsis rate was low (6.3%), occurring in 
patients not treated with prophylactic growth factor, and 
there were four infection-related deaths. Interestingly, there 
were no grade 3/4 cardiac events and patients experienced a 
trend toward pain improvement on self-reported quality of 
life studies. In a subset analysis of 746 men enrolled in com-
passionate use and early access programs, safety, as reported 
based on age, ,70, 70–74, and .75 years was reviewed.9 In 
a multivariable analysis, patients aged .75 years and those 
with neutrophil count ,4,000/mm3 at baseline were at the 
highest risk of neutropenia and complications and prophy-
lactic G-CSF mitigated these risks.
Cabazitaxel dose selection
The FDA-approved dose of cabazitaxel (25 mg/m2) was 
based on the TROPIC trial, but questions remained whether a 
lower dose could still be as efficacious with less toxicity. This 
led to the FDA-mandated PROSELICA study, a randomized 
Phase III noninferiority study of cabazitaxel 20 mg/m2 (C20) 
vs 25 mg/m2 (C25) in 1200 patients with mCRPC previously 
treated with docetaxel (D).10 Of the 10 planned treatments, 
both groups completed a similar number of median cycles 
of therapy, 6 (C20) and 7 (C25), with more dose reductions 
in the 25 mg/m2 arm. There were more grade 3/4 treatment-
related toxicities and more treatment-related deaths in C25 
compared to C20. However, a sub group analysis showed that 
patients treated with prior second-generation antiandrogens 
(enzalutamide or abiraterone) had a trend toward better out-
comes with C25 than C20. Patients treated on the 25 mg/m2 
arm had significantly improved PSA response rates (42.9% 
vs 29.5%, P,0.001) and improved radiographic response, 
but there was no difference in PFS. OS was 13.4 months in 
the C20 arm, which was not inferior to 14.5 months in the 
C25 cohort (hazard ratio [HR] 20 vs 25, HR=1.024). This 
met the FDA-mandated prespecified noninferiority endpoint, 
which maintained 50% of the OS benefit of the C25 dose in 
the originally reported TROPIC trial.
Alternative cabaztiaxel dosing regimens that have been 
explored include a weekly schedule for “unfit” mCRPC 
patients. Investigators defined unfit as patients with Eastern 
Cooperative Oncology Group status .2, history of dose 
reduction with docetaxel due to febrile neutropenia, or 
history of radiation affecting .25% of the bone marrow 
reserve. MTD had previously been established as cabazitaxel 
10 mg/m2 given for 4 weeks on a 5-week cycle.11 Sixty-six 
unfit patients with mCRPC were evaluated, 87% of whom 
had metastatic bone disease. Overall, treatment was well 
tolerated. The most common grade 3/4 toxicities were 
asthenia (10.6%), anemia (6%), thrombocytopenia (4.5%), 
and neutropenia (3%). There were no occurrences of febrile 
neutropenia or grade 4 diarrhea. A decline in PSA by 50% 
was observed in 32.7%. The median OS with weekly dosing 
was 14.2 months, making this regimen a reasonable option 
for patients with an impaired performance status.12
Treatment sequencing
Determining the ideal sequencing of therapy is difficult, as 
there are no prospective head-to-head trials evaluating all 
the available treatments for mCRPC. Comparison between 
individual trials certainly has its own limitations as studies 
vary in their design, comparator arm, and patient character-
istics. As such, clinicians rely heavily on large retrospective 
analyses to draw conclusions for optimal therapy sequenc-
ing post-docetaxel. To date, no clear prospective data exist 
to support a sequence of subsequent therapy following 
docetaxel.
Cabazitaxel following second-generation 
hormone therapy
Though the sequence and biological rationale for the use of 
docetaxel followed by cabazitaxel is clear, little is known 
about resistance mechanisms and optimal sequencing of the 
other FDA-approved agents for mCRPC. There is a sug-
gestion that resistance to abiraterone may also confer cross 
resistance to docetaxel, but this is not known for cabazitaxel.13 
In the aforementioned PROSELICA trial, patients who were 
previously treated with abiraterone or enzalutamide experi-
enced significantly better rates of PSA response and radio-
graphic responses with cabazitaxel 25 mg/m2 compared to 
those treated with 20 mg/m2, though no survival differences 
were noted. These are probably the most robust prospective 
data on the sequence of cabazitaxel with second-generation 
androgen inhibitors.
Several retrospective studies have addressed the activity 
of cabazitaxel following abiraterone. In a multicenter retro-
spective Israeli study in subjects on abiraterone compassion-
ate use programs following docetaxel, 24 patients received 
subsequent cabazitaxel for a median of four cycles.14 Most 
patients were treated with growth factor support at the outset 
of therapy. A PSA response of .50% decline from baseline 
was seen in 31% of patients, and RECIST response was seen 
in 13% of patients, with a median survival of 8.2 months 
from initiation of cabazitaxel, thus supporting its activity 
after progression on abiraterone.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
14
0.
23
3.
14
 o
n 
19
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4092
Patel and Hoffman-Censits
In a single-center retrospective study from the Royal 
Marsden Hospital, 59 patients who had progressed after 
docetaxel and who had received cabazitaxel for mCRPC 
were identified. Thirty-two patients had received prior 
abiraterone for a median of 7 months, four patients had prior 
enzalutamide for a median of 1 month, and five patients had 
received both.15 A median of six cabazitaxel cycles were 
delivered, with an OS of 15.8 months, similar to that reported 
in the TROPIC study. Lack of response to initial abiraterone 
and enzalutamide therapy in this retrospective study did not 
appear to influence the response to cabazitaxel.
In a French and Canadian study, 79 men with mCRPC 
were treated with a median of six cycles of cabazitaxel 
25 mg/m2 post a median of eight cycles of docetaxel and 
4.8 months of abiraterone.16 Patients experienced an OS of 
10.9 months, and PSA decline .50% in 35% of patients.
In a retrospective series from the US Oncology Practice 
Network, sequences of docetaxel, cabazitaxel, and abirater-
one were reviewed.17 One hundred thirteen patients received 
all three agents, of whom 77 patients sequenced docetaxel 
(D), followed by cabazitaxel (C), followed by abiraterone (A) 
and 36 patients were treated in the DAC sequence. Patients 
tolerated more cycles in the DCA compared to the DAC 
sequence (six vs four cycles, P,0.001), with improved OS in 
the DCA sequence as well (18.2 vs 11.8 months, P=0.0023). 
The authors speculate that the additional cycles of cabazi-
taxel tolerated may contribute to the clinical benefits of the 
DCA sequence.
Finally, the impact of previous treatment with second-
generation androgen inhibition on cabazitaxel efficacy was 
evaluated in a Phase II Dutch trial of cabazitaxel 25 mg/m2 
with prednisone, with or without budesonide to prevent 
chemotherapy-induced diarrhea.18 Forty-four of 114 evalu-
able patients had received either enzalutamide (3), abirater-
one (39), or both (2) following docetaxel, prior to initiating 
cabazitaxel while the remainder (70) proceeded directly 
to cabazitaxel after docetaxel failure. Other than slightly 
lower albumin, there were no baseline differences between 
those who had and had not received a second-generation 
therapy. There were no significant differences in rates of PSA 
response .50% to cabazitaxel between the groups treated 
with and without second-generation antiandrogen agents 
(34% vs 40%, P=0.53), or there was a significant difference 
in the median OS of 13 vs 14 months.
These retrospective studies help highlight the efficacy 
of cabazitaxel in mCRPC patients who failed docetaxel and 
AR-directed therapies, suggesting that the mechanism of resis-
tance for each may be different. Identifying mCRPC patients 
who may benefit from earlier initiation of cabazitaxel was 
an integral driving force behind the prospectively designed 
TAXYNERGY trial.19 Investigators looked at overcoming 
inherent taxane resistance in chemotherapy-naive mCRPC 
by utilizing an early switch model. Patients previously treated 
with AR therapies (44.4%), radiation, or immunotherapy were 
randomized 2:1 to docetaxel or cabazitaxel and re-evaluated 
at 12 weeks for PSA decline of $30% from baseline. If PSA 
did not drop sufficiently, they were switched to the other 
taxanes. Primary endpoint was to improve upon the historical 
PSA response rate (.50% decline) observed in the TAX327 
of 45.4%. In an intention to treat analysis, 55.6% of patients 
achieved a PSA decline of .50% by the end of the study 
reaching statistical significance. PSA response rate in patients 
previously treated with AR therapies was lower (44%) than 
AR-naive patients (68%). Fifteen of 63 patients switched 
taxane therapy after 12 weeks due to poor PSA response and 
46.7% (7) of these patients achieved a PSA decline of .50%. 
Median OS was not reached. Correlation of patient response 
with circulating tumor cells (CTCs) is described later (refer 
“Biomarkers of efficacy” section). Further trials to determine 
benefit of early taxane switching in mCRPC are warranted with 
a focus on patients who have failed AR-directed therapies.
Cabazitaxel prior to second-generation 
hormone therapy
While cabazitaxel seems to retain activity after exposure to 
abiraterone or enzalutamide, several studies have evaluated 
the impact of using it prior to these hormonal agents. In the 
multicenter retrospective CAST study from the Netherlands, 
patients with mCRPC following docetaxel were treated with 
cabazitaxel and abiraterone sequential therapy.20 Sixty-three 
men received cabazitaxel followed by abiraterone (CA), and 
69 were treated in the reverse sequence (AC). There was 
a significant difference in baseline age, with the median 
age of the CA patients 65.6 years and the mean age of AC 
patients 69.8 years (P,0.001). Apart from age, there were 
no other baseline tumor-related differences and both groups 
received similar number of prior docetaxel cycles. In the CA 
group, men received a mean of 7.3 cabazitaxel cycles, which 
was significantly more compared to 4.6 in the AC group 
(P,0.001). There was no significant difference in OS based 
on treatment sequence, with median OS 19.1 months for CA-
treated patients and 17.0 months for AC-sequenced patients. 
Hospitalization for febrile neutropenia occurred in 9.5% CA 
patients and 14.5% AC-treated individuals, and there were 
more deaths within 30 days in the CA when compared to the 
AC sequence, though most were due to disease progression.
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Contrary to the CAST study, the results from a large 
retrospective Italian study seemed to suggest a slight survival 
advantage when cabazitaxel (C) was used prior to a second-
generation novel hormone therapy (NHT) abiraterone and 
enzalutamide.21 Four-hundred seventy-six patients with 
mCRPC who had received at least two therapies post-doc-
etaxel (D) were grouped by treatment history: D–NHT–C, 
D–C–NHT, and D–NHT–NHT. The median OS from initia-
tion of the second agent was statistically significant at 12.9, 
14.2, and 8.8 months, respectively (P=0.01) with the longest 
OS in the patients treated with cabazitaxel in the second 
line. Investigators did not report on the median number 
of cycles of cabazitaxel for each group, but this might be 
a critical factor that can help explain the OS benefit in the 
D–C–NHT group.
Similar results were seen with a retrospective review of 
574 mCRPC cases from the FLAC international database.22 
Patients again were separated into groups based on their 
treatment history: Group 1: D–C–NHT; Group 2: D–NHT–C; 
and Group 3: D–C. The median number of cycles was 7 for 
docetaxel and 6 for cabazitaxel. The OS from first docetaxel 
cycle was 40.1, 37.1, and 30.1 months, respectively. Inves-
tigators note that the activity of cabazitaxel did not seem to 
be influenced by prior NHT use. Although the trend supports 
improved outcomes with cabazitaxel in the second line, the 
data are retrospective and the possibility of a patient selec-
tion bias toward healthier patients must be recognized. This 
concern is reinforced by the multivariate analysis that showed 
patients with a lower PSA, longer ADT response times, and 
lack of clinical progression at the time of docetaxel initiation 
overall had a better prognosis.
Rechallenging patients with cabazitaxel
Data regarding cabazitaxel rechallenge in fit patients with 
history of good response are limited, but one retrospective 
study looked at 70 mCRPC patients previously treated with 
docetaxel (D), cabazitaxel (C), and a second-generation anti-
androgen who were retreated with cabazitaxel.23 A majority 
of the patients (74%) had received D–NHT–C, while 24% 
received D–C–NHT. The median time from last cabazitaxel 
dose was 8.6 months. Rechallenge doses of cabazitaxel 
every 3 weeks were 25 mg/m2 (58% of patients), 20 mg/m2 
(27%), and 16 mg/m2 (14.3%). Less than half (47%) of the 
patients required growth factor support. The mean PFS was 
7.8 months with an OS of 13.4 months from initiation of 
rechallenge. Grade 3/4 toxicities were 18%, and there were no 
episodes of febrile neutropenia. As investigators remarked, 
these promising data may be skewed by patient selection 
bias, given that all participants were assessed to be fit for 
chemotherapy despite at least three other lines of therapy.
Cabazitaxel in the first-line treatment of 
mCRPC
In 2016, a large-scale trial provided information on caba-
zitaxel compared to docetaxel for first-line treatment in 
chemotherapy-naive patients in the FIRSTANA study.24 This 
was a three-arm trial comparing two doses of cabazitaxel, 20 
and 25 mg/m2, to docetaxel 75 mg/m2 in men with chemo-
therapy-naive mCRPC. A total of 1168 patients at 159 centers 
participated, very few of whom were previously treated with 
second-line hormone therapy. The primary endpoint was OS, 
and it was hypothesized that cabazitaxel would be superior to 
docetaxel. The study failed to meet this superiority primary 
endpoint, as there was no difference in OS between caba-
zitaxel and docetaxel at either dose, with survival ranging 
from 24.3 to 25.2 months between the groups, and there was 
no difference in PFS. The median number of cycles was 9. 
Dose delays and reductions were highest in the cabazitaxel 
25 mg/m2 arm, as were rates of neutropenic fever, infections, 
diarrhea, and hematuria. Peripheral neuropathy, stomatitis, 
edema, alopecia, and nail changes were more pronounced 
in the docetaxel arm compared with the cabazitaxel arm 
(Table 1). These data continue to support the use of doc-
etaxel as first-line therapy of patients with mCRPC. The 
discussant of this important and informative Phase III trial, 
Dr Raghavan, also reviewed the significant cost difference 
between docetaxel and cabazitaxel, highlighting the value, 
as well as safety and efficacy of docetaxel in the first line.25 
More prospective, randomized trials of cabazitaxel in the 
first line are in progress and will hopefully clarify where it 
belongs in treatment sequencing of mCRPC.
Table 1 FIRSTANA (NCT01308567) side effect profile of 
docetaxel vs cabazitaxel as first-line treatment in mCRPC
TEAEs .5% Docetaxel 
75 mg/m2 (%)
Cabazitaxel 
25 mg/m2 (%)
All grades Grade 3/4 All grades Grade 3/4
Febrile neutropenia 8.3 8.3 12 12
Neutropenic infection 4.9 4.1 6.1 5.9
Diarrhea 37 2.3 49.9 5.6
Stomatitis 13.7 0.8 6.6 0.3
Hematuria 3.6 0.3 25.1 3.6
Peripheral neuropathy 25.1 2.1 12.3 0
Peripheral edema 20.4 1.6 7.7 0.3
Alopecia 39 0 13 0
Nail disorders 9 0.3 0.8 0
Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; TeAes, 
treatment-emergent adverse events.
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Cabazitaxel in combination with a second 
agent
Several trials have tried to enhance the antitumor activity of 
cabazitaxel by adding a second agent with a distinct mechanism 
of action. Researchers propose that targeting prostate cancer 
cells in two separate ways will lead to greater cytotoxicity 
and diminish chances for developing resistance. In the Phase 
III Affinity trial, investigators randomized 635 mCRPC 
patients who had failed docetaxel to cabazitaxel ± curtisen 
(OGX-011), a novel agent designed to inhibit the production 
of clusterin, a cytoprotective protein that is upregulated in 
cancer cells exposed to chemotherapy.26 Cabaztiaxel was 
given once every 3 weeks at 25 mg/m2 and curtisen was given 
weekly at 640 mg intravenously for a total of 10 cycles. The 
study unfortunately did not reach its primary endpoint of OS 
(14.2 vs 13.4 months; P=0.529).
Cabazitaxel is also being studied with a small-molecule 
inhibitor tasquinimod in the Phase I CATCH trial.27 Tasquini-
mod limits the activity of myeloid-derived suppressor cells 
(MDSCs), which accumulate in the tumor microenvironment 
and inhibit the antitumor activity of T, natural killer, and den-
dritic cells. The small molecule binds to protein S100A8/A9 
and interrupts the positive feedback of further MDSC recruit-
ment. The study established a maximum tolerated dose (MTD) 
of cabazitaxel 25 mg/m2 and tasquinimod 0.5 mg daily with a 
lead-in of 0.25 mg daily for 3 weeks. Observed grade 3/4 events 
were fatigue, febrile neutropenia, and liver dysfunction.
In addition to novel drugs, cabazitaxel is being studied in 
combination with other agents used in mCRPC. Single-arm, 
early-phase trials have demonstrated the tolerability and 
efficacy of cabazitaxel at 25 mg/m2 every 3 weeks with abi-
raterone 1,000 mg daily.28 These include patients previously 
treated with docetaxel and at least 3 months of abiraterone. Of 
the 26 patients, 46.2% achieved a PSA response, which was 
higher than the historic controls seen with abiraterone alone 
(29%) and cabazitaxel alone (39%). The median PSA–PFS 
was 6.9 months, and a subset of patients (6) had a sustained 
PSA response at 6 months. Adverse events observed were 
similar to those seen with the drugs individually. Additional 
randomized studies of cabazitaxel and abiraterone are ongoing 
as are early-phase studies of cabazitaxel with enzalutamide.
Cabazitaxel has also been paired with other chemotherapy 
agents such as carboplatin with the hypothesis that patients 
with aggressive variant of prostate cancer (AVPC) may have 
better outcomes with a taxane–platinum combination.29 Pre-
vious work by Aparicio et al identified the presence of at least 
two mutations in p53, Rb1, and/or PTEN in androgen indif-
ferent tumor samples and postulated that their presence would 
correlated with platinum response. Clinical characteristics of 
AVPC were defined as histological presence of small cell, 
visceral, or lytic bone disease at presentation, bulky tumor, 
or adenopathy, PSA ,10, despite high disease burden. One 
hundred sixty men were randomized to cabazitaxel 25 mg/m2 
± carboplatin at area under the curve 4 every 3 weeks. Median 
PFS was significantly better in the combination arm at 7.0 vs 
4.6 months for cabazitaxel alone (P=0.004). This benefit was 
greater in those patients with AVPC with median PFS 8 vs 
4.5 months (P=0.0036). Molecular profiling of tumor biop-
sies and ctDNA are in process, but early results suggest that 
the molecular definition on AVPC better predicts response to 
platinum–taxane therapy compared to the clinical definition. 
Investigators are planning a Phase III trial powered for OS.
Biomarkers of efficacy
In a post hoc analysis of the patients treated with cabazitaxel 
on the TROPIC study, those who developed grade .3 neu-
tropenia had significantly prolonged OS (16.3 vs 14 months, 
P=0.035), PFS (5.3 vs 2.6 months), and a higher rate of PSA 
response of .50% than those who did not.30 There was a trend 
that the frequency of neutropenia was associated with OS and 
PFS. The authors also observed the effect of neutrophil-to-
lymphocyte ratio (NLR) upon outcomes and defined high 
baseline NLR .3 and low ,3. Analyzed together, those 
with grade .3 neutropenia and low NLR experienced the 
longest OS of 19.2 months, while those with high NLR and 
no neutropenia had a 12.9-month OS. In the minority of 
patients treated with G-CSF after cycle 1 in TROPIC, there 
did not seem to be an effect upon survival. These authors 
suggest that a tailored approach to cabazitaxel dosing based 
on neutropenia may enhance patient outcomes.
With the advent of precision medicine, research has 
focused on the development of predictive biomarkers to aid 
in treatment selection. Presence of the AR splice variant 7 
(AR-V7) in CTCs from men with mCRPC appears to cor-
relate with treatment resistance to abiraterone and enzalu-
tamide.31 Several investigators have sought to determine if 
the same resistance is true for chemotherapy as well. Thirty-
seven men starting either docetaxel or cabazitaxel chemo-
therapy were prospectively evaluated at a single institution 
to determine if AR-V7 in CTCs was correlated to clinical 
outcomes.32 There were no significant differences between 
subjects with and without measurable AR-V7 with respect 
to response to taxane chemotherapy; however, as expected, 
AR-V7-positive men responded better to taxanes than to 
second-generation hormone therapy.
CTCs were also studied in the aforementioned 
TAXYNERGY trial. Investigators hypothesized that 
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taxane-sensitive tumor cells would have a decrease in AR 
nuclear localization (ARNL) due to disruption of microtubule 
activity. The ARNL percentage in CTCs was measured on 
days 1 and 8 of cycle 1 of taxane therapy. A taxane-induced 
decrease in mean percentage of ARNL significantly corre-
lated with a higher rate of PSA response of $50% decline 
in PSA (72.2% vs 12.5%, P=0.009). This evidence supports 
preclinical data that the anti-tumor activity of taxanes in pros-
tate cancer is related to their disruption of AR trafficking from 
the cytoplasm to the nucleus and suggests that persistence 
of ARNL in setting of taxane treatment may be a marker of 
therapy resistance.19 Larger studies are needed to corroborate 
this potential biomarker of taxane sensitivity.
Patient selection
The development of treatment predictive biomarkers is a prom-
ising field but is still under investigation in prostate cancer. 
Based on the above studies, cabazitaxel should be reserved off 
trial for men with mCRPC following docetaxel. Retrospective 
data suggest that it retains significant activity after progression 
on second-generation antiandrogens. Proactive management 
of toxicity, specifically neutropenia, is critical and should 
especially be considered in patients older than 75 years with 
baseline absolute neutrophil count ,4,000/mm3. Use of 
cabazitaxel at lower dose of 20 mg/m2 offers similar OS, but 
a subset of patients who tolerate treatment with low NLR may 
have better outcomes. Similarly, a low-dose weekly regimen 
may be reasonable in patients with Karnofsky Performance 
Score ,70%. Rechallenging patients with cabazitaxel who 
previously had a good response is a promising option to help 
extend survival. With regard to patient preference, prospec-
tively collected data outcomes from the 3,000 men in the 
Prostate Cancer Registry showed that patients on abiraterone 
or enzalutamide as second-line treatment after docetaxel 
reported a higher rate of clinically meaningful improvement 
in quality of life compared to those treated with cabazitaxel 
despite similar time to disease progression.33 Interestingly, the 
cabazitaxel group reported lower rates of clinically meaning-
ful deterioration in their quality of life. To date, the time to 
disease progression is similar among all agents.
Ultimately, more prospective data are needed. Tables 2 
and 3 briefly describe the latest trials registered on 
Table 2 Recently completed clinical trials of cabazitaxel in mCRPC
NCT number Phase Description Results
Single-agent cabazitaxel in mCRPC
NCT01254279 iii UK eAP to assess quality of life and safety data on 
cabazitaxel 25 mg/m2 in mCRPC previously treated with 
docetaxel8
Almost 1/3 of patients completed $10 cycles in the UK 
eAP. QOL was stable with trends to improved eQ-5D and 
vAS scores. improved or stable pain was observed in the 
majority of patients continuing therapy
NCT00417079 iii TROPiC: cabazitaxel vs mitoxantrone in mCRPC 
previously treated with docetaxel6
Updated cabazitaxel prolongs OS at 2 years vs mitoxantrone 
and has low rates of peripheral neuropathy. Palliation benefits 
of cabazitaxel were comparable to those of mitoxantrone
NCT01649635 iv PROSPeCTA: to assess effectiveness of prophylactic 
treatment of hematological complications (grade $3 
neutropenia) resulting from cabazitaxel treatment in 
mCRPC previously treated with docetaxel
Not posted
NCT02074137 iv evaluation of safety of cabazitaxel in patients with 
mCRPC previously treated with docetaxel
Not posted
NCT02441894 iv PeGAZUS: assess tolerability of cabazitaxel with 
primary prophylaxis PeG-G-CSF in mCRPC previously 
treated with docetaxel
Not posted
NCT01324583 i Dose-escalation study with cabazitaxel and 
prednisolone in patients with hormone refractory 
prostate cancer previously treated with docetaxel
Not posted
Cabazitaxel dosing in mCRPC
NCT01308580 iii PROSeLiCA: cabazitaxel at 20 vs 25 mg/m2 with 
prednisone for the treatment of mCRPC10
Cabaztiaxel 20 mg/m2 demonstrates noninferiority for 
OS compared to Cabaztiaxel 25 mg/m2 and an improved 
overall safety profile
NCT01541007 ii ConCab: assess tolerability of cabazitaxel 25 mg/m2 
every three weeks vs 10 mg/m2 for 5 consecutive 
weeks of a 6-week cycle
Not posted
NCT01518283 ii Study of weekly cabazitaxel for unfit mCRPC12 Cabazitaxel 10 mg/m2 weekly is tolerable and effective in 
unfit patients and results in OS of 14.2 months
NCT01558219 ii Safety and efficacy of biweekly dosing of cabazitaxel in 
second line treatment of mCRPC34
Cabazitaxel 16 mg/m2 biweekly without G-CSF is tolerable 
with 16% neutropenia and 1.7% neutropenic infection
(Continued)
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Table 3 Ongoing clinical trials of cabazitaxel in prostate cancer
NCT number Phase Description
Cabazitaxel in high risk or locally advanced disease
NCT01952223 iii PeACe2: assess effect of neoadjuvant cabazitaxel and pelvic XRT with ADT in high-risk localized prostate cancer
NCT01420250 i weekly cabazitaxel with iMRT and ADT in locally advanced prostate cancer
NCT01978873 iii SenciCab: cabazitaxel + ADT vs ADT alone in metastatic or high-risk disease
NCT02543255 ii ACDC trial: neoadjuvant cabazitaxel and abiraterone with ADT in high-risk prostate cancer
Cabazitaxel sequencing in mCRPC
NCT01308567 iii FIRSTANA: cabazitaxel vs docetaxel both with prednisone as first line in patients with mCRPC
NCT02044354 iii CABA-DOC: patient preference between first-line cabazitaxel vs docetaxel in mCRPC
NCT02844582 ii Cabazitaxel/prednisone as first line therapy in mCRPC
NCT02254785 ii Compare the clinical benefit of cabazitaxel vs abiraterone or enzalutamide in poor prognosis mCRPC patients
NCT02485691 iv CARD: compare cabazitaxel vs AR-directed agents in mCRPC previously treated with docetaxel and who 
rapidly failed a prior AR agent
NCT02512458 ii CABA-BONe: explore the effect of cabazitaxel on survival pathways and androgen signaling in the tumor 
microenvironment (bone marrow) of patients with mCRPC
NCT02903160 ii PRINT: determine the clinical benefits of using a rapidly cycling, non-cross-reactive regimen of FDA-
approved prostate cancer therapeutic agents in the management of CRPC
Alternate dosing of cabazitaxel in mCRPC
NCT02961257 iii CABASTY: safety of biweekly cabazitaxel at 16 mg/m2 vs triweekly cabazitaxel at 25 mg/m2 in elderly mCRPC 
patients previously treated with docetaxel
Cabazitaxel combined with AR agent in mCRPC
NCT02218606 ii Determine pathologic effects of abiraterone with or without cabazitaxel on mCRPC tissue
NCT02522715 i and ii Assess safety/tolerability of enzalutamide and cabazitaxel combination in mCRPC
NCT03110588 i PACe: determine the feasibility and recommended dose of the combination of four drugs (prednisone, 
abiraterone, and cabazitaxel and enzalutamide as first-line therapy for mCRPC
(Continued)
Table 2 (Continued)
NCT number Phase Description Results
Sequencing of single-agent cabazitaxel in mCRPC
NCT01718353 ii TAXYNERGY: explore the benefit of an early switch 
from docetaxel to cabazitaxel and vice versa in mCRPC 
who do not achieve $30% PSA decline from baseline 
by cycle 4 and correlated with CTCs19
PSA reduction in 55.6% of patients compared to historic 
rate of 45.4% in TAX327. Nearly 90% of men with 
progressive chemo-naive mCRPC have detectable CTCs 
with higher CTC counts associated with adverse prognostic 
variables. Lower percent of nuclear AR was associated with 
visceral metastases, suggesting that progressive visceral 
CRPC may be less AR driven. Decrease in ARNL on day 8 
of taxane treatment correlates with PSA response
NCT01576029 ii SwiTCH: compare the continuation of treatment with 
docetaxel vs switching to cabazitaxel regarding the time 
to PSA progression
Not posted
Cabazitaxel with AR agent in mCRPC
NCT01511536 i and ii Determine MTD and efficacy of cabazitaxel with 
abiraterone in mCRPC progressed on docetaxel28
Phase i: MTD-cabazitaxel 25 mg/m2 every 21 days with 
abiraterone 1,000 mg daily; Phase II: statistically significant 
PSA reduction in 46% of patients
NCT01845792 ii Study of cabazitaxel with or without abiraterone/
prednisone in mCRPC
Not posted
Cabazitaxel with other agents in mCRPC
NCT01513733 i CATCH: determine safety and MTD of tasquinimod 
in combination with cabazitaxel in men with 
chemorefractory mCRPC27
MTD established at Cabaztiaxel 25 mg/m2 every 3 weeks 
with tasquinimod 0.5 mg daily with a 3-week lead-in at 
0.25 mg daily
NCT01505868 ii Study of cabazitaxel with or without carboplatin 
(AUC 4) in patients with mCRPC29
Combination with significantly better PFS overall 
(7 vs 4.6 m) and in aggressive subtype (8 vs 4.5 m)
NCT01578655 iii AFFiNiTY: determine if addition of curtisen to cabazitaxel/
prednisone enhances OS and PFS in mCRPC26
No statistically significant improvement in OS
Abbreviations: AR, androgen receptor; ARNL, AR nuclear localization; AUC, area under the curve; CRPC, castration-resistant prostate cancer; CTCs, circulating tumor 
cells; EQ-5D, Descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression); 
G-CSF, granulocyte colony stimulating factor; m, months; mCRPC, metastatic castration-resistant prostate cancer; MTD, maximum tolerated dose; OS, overall survival; 
PEG, polyethylene glycol; PFS, progression-free survival; PSA, prostate specific antigen; QOL, quality of life; UK EAP, United Kingdom Early Access Program; VAS, visual 
analogue scale.
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ClinicalTrials.gov that will hopefully provide greater insight 
on cabazitaxel sequencing as well as alternate dosing patterns 
or in combination with other therapies.
Conclusion
Treatment of mCRPC is dynamic and complex. Until the 
development of predictive treatment biomarkers, clinicians 
rely on data from prospective clinical trials as well as the 
conclusions drawn from retrospective analyses. In this 
review, we examine the evidence for the role of cabazitaxel 
in mCRPC. The FIRSTANA data continue to support the 
chemotherapy sequence of docetaxel followed by cabazi-
taxel. This is also supported by other retrospective studies. 
However, in looking at past and future studies, it is important 
to consider that patients sequenced with docetaxel and then 
cabazitaxel may be fitter, thus confounding the success of 
DC sequencing. Randomized controlled trials are needed to 
address this and other variables.
Toxicity from TROPIC and subsequent trials continue to 
show that treatment-related neutropenia and complications 
remain significant and can be modified by the use of pro-
phylactic growth factor support, particularly for vulnerable 
populations of age .75 years and baseline absolute neutro-
phil count ,4,000/mm3. The PROSELICA data suggest that 
use of cabazitaxel at 20 mg/m2 is perhaps a better value when 
compared with 25 mg/m2 as it provided a similar survival 
outcome with less toxicity. This must be weighed against the 
subgroup analysis showing that patients with prior treatment 
with abiraterone or enzalutamide had better outcomes on C25 
vs C20. At this time, dosing decisions should continue to be 
individualized based on the patient’s treatment history and 
performance status.
Future directions of cabazitaxel will be determined by 
ongoing trials. Its use in combination with AR therapies 
and other experimental agents may potentially provide bet-
ter disease control in mCRPC and help to extend patient 
survival.
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